KR101070886B1 - A composition comprising pachydictyon coriaceum extract - Google Patents
A composition comprising pachydictyon coriaceum extract Download PDFInfo
- Publication number
- KR101070886B1 KR101070886B1 KR1020090007594A KR20090007594A KR101070886B1 KR 101070886 B1 KR101070886 B1 KR 101070886B1 KR 1020090007594 A KR1020090007594 A KR 1020090007594A KR 20090007594 A KR20090007594 A KR 20090007594A KR 101070886 B1 KR101070886 B1 KR 101070886B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- composition
- effect
- skin
- bamboo
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 107
- 239000000203 mixture Substances 0.000 title claims abstract description 52
- 241000659328 Dictyota coriacea Species 0.000 title abstract description 3
- 230000003779 hair growth Effects 0.000 claims abstract description 20
- 230000037303 wrinkles Effects 0.000 claims abstract description 15
- 230000003579 anti-obesity Effects 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 235000017166 Bambusa arundinacea Nutrition 0.000 claims description 41
- 235000017491 Bambusa tulda Nutrition 0.000 claims description 41
- 241001330002 Bambuseae Species 0.000 claims description 41
- 235000015334 Phyllostachys viridis Nutrition 0.000 claims description 41
- 239000011425 bamboo Substances 0.000 claims description 41
- 239000008194 pharmaceutical composition Substances 0.000 claims description 16
- 238000009472 formulation Methods 0.000 claims description 14
- 239000000843 powder Substances 0.000 claims description 11
- 208000008589 Obesity Diseases 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 8
- 244000309146 drought grass Species 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- 235000020824 obesity Nutrition 0.000 claims description 8
- 239000000243 solution Substances 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- 239000006210 lotion Substances 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 240000003291 Armoracia rusticana Species 0.000 claims description 3
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 239000006072 paste Substances 0.000 claims description 3
- 239000004094 surface-active agent Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 2
- 235000013376 functional food Nutrition 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 56
- 235000013305 food Nutrition 0.000 abstract description 13
- 230000002087 whitening effect Effects 0.000 abstract description 12
- 230000003078 antioxidant effect Effects 0.000 abstract description 11
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 10
- 230000001737 promoting effect Effects 0.000 abstract description 10
- 230000006872 improvement Effects 0.000 abstract description 6
- 229940079593 drug Drugs 0.000 abstract description 4
- 239000003814 drug Substances 0.000 abstract description 4
- 210000003491 skin Anatomy 0.000 description 36
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
- 238000002360 preparation method Methods 0.000 description 24
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 21
- 230000002401 inhibitory effect Effects 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 229960000271 arbutin Drugs 0.000 description 17
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 17
- 239000002904 solvent Substances 0.000 description 16
- 238000012360 testing method Methods 0.000 description 16
- -1 isoprotanol Chemical compound 0.000 description 14
- 239000000523 sample Substances 0.000 description 14
- 230000008099 melanin synthesis Effects 0.000 description 12
- 102000029816 Collagenase Human genes 0.000 description 11
- 108060005980 Collagenase Proteins 0.000 description 11
- 244000074881 Conyza canadensis Species 0.000 description 10
- 235000004385 Conyza canadensis Nutrition 0.000 description 10
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 10
- 102000003425 Tyrosinase Human genes 0.000 description 10
- 108060008724 Tyrosinase Proteins 0.000 description 10
- 229960002424 collagenase Drugs 0.000 description 10
- 239000002609 medium Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 108010035532 Collagen Proteins 0.000 description 9
- 102000008186 Collagen Human genes 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 229920001436 collagen Polymers 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 7
- 102000000588 Interleukin-2 Human genes 0.000 description 7
- 108010002350 Interleukin-2 Proteins 0.000 description 7
- 238000001816 cooling Methods 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 230000003834 intracellular effect Effects 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 239000012071 phase Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 201000004384 Alopecia Diseases 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 229920006008 lipopolysaccharide Polymers 0.000 description 6
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 239000005089 Luciferase Substances 0.000 description 5
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 5
- 102100036201 Oxygen-dependent coproporphyrinogen-III oxidase, mitochondrial Human genes 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- 235000020710 ginseng extract Nutrition 0.000 description 5
- 230000003676 hair loss Effects 0.000 description 5
- 208000024963 hair loss Diseases 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 235000021395 porridge Nutrition 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 241000199919 Phaeophyceae Species 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 4
- 230000032683 aging Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- 230000001186 cumulative effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000003937 drug carrier Substances 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000019612 pigmentation Effects 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 3
- ITBPIKUGMIZTJR-UHFFFAOYSA-N [bis(hydroxymethyl)amino]methanol Chemical compound OCN(CO)CO ITBPIKUGMIZTJR-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 3
- 229910052782 aluminium Inorganic materials 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 235000013339 cereals Nutrition 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 239000000787 lecithin Substances 0.000 description 3
- 235000010445 lecithin Nutrition 0.000 description 3
- 229940067606 lecithin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 231100001083 no cytotoxicity Toxicity 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 230000003658 preventing hair loss Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical group C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- 241000700198 Cavia Species 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 208000001382 Experimental Melanoma Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 244000274883 Urtica dioica Species 0.000 description 2
- 235000009108 Urtica dioica Nutrition 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000001153 anti-wrinkle effect Effects 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004945 emulsification Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 230000003659 hair regrowth Effects 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000001294 propane Substances 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000004043 responsiveness Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000008470 skin growth Effects 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 108090000672 Annexin A5 Proteins 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010056489 Coronary artery restenosis Diseases 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000199916 Dictyotales Species 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 241000195955 Equisetum hyemale Species 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 1
- 206010061307 Neck deformity Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 208000018262 Peripheral vascular disease Diseases 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 101710147108 Tyrosinase inhibitor Proteins 0.000 description 1
- 108010006886 Vitrogen Proteins 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 231100000360 alopecia Toxicity 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- CJPQIRJHIZUAQP-MRXNPFEDSA-N benalaxyl-M Chemical compound CC=1C=CC=C(C)C=1N([C@H](C)C(=O)OC)C(=O)CC1=CC=CC=C1 CJPQIRJHIZUAQP-MRXNPFEDSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000003710 calcium ionophore Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 229960001714 calcium phosphate Drugs 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960003340 calcium silicate Drugs 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 1
- 229940081733 cetearyl alcohol Drugs 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 230000036570 collagen biosynthesis Effects 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- CJAONIOAQZUHPN-KKLWWLSJSA-N ethyl 12-[[2-[(2r,3r)-3-[2-[(12-ethoxy-12-oxododecyl)-methylamino]-2-oxoethoxy]butan-2-yl]oxyacetyl]-methylamino]dodecanoate Chemical compound CCOC(=O)CCCCCCCCCCCN(C)C(=O)CO[C@H](C)[C@@H](C)OCC(=O)N(C)CCCCCCCCCCCC(=O)OCC CJAONIOAQZUHPN-KKLWWLSJSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- UBHWBODXJBSFLH-UHFFFAOYSA-N hexadecan-1-ol;octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO.CCCCCCCCCCCCCCCCCCO UBHWBODXJBSFLH-UHFFFAOYSA-N 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 238000001794 hormone therapy Methods 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 239000000367 immunologic factor Substances 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 229950011392 sorbitan stearate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9706—Algae
- A61K8/9711—Phaeophycota or Phaeophyta [brown algae], e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 참가죽그물바탕말(Pachydictyon coriaceum) 추출물을 포함하는 조성물에 관한 것이다. 상기 참가죽그물바탕말은 미백 효과, 주름 개선 효과, 발모 촉진 효과, 항염증 효과, 항산화 효과, 항비만 효과 등을 나타내어, 이를 목적으로 하는 화장료, 약품 및 식품에 유용하게 적용할 수 있다. The present invention relates to a composition comprising the extract Pachydictyon coriaceum . The participating moth can be usefully applied to cosmetics, medicines and foods for this purpose by showing a whitening effect, wrinkle improvement effect, hair growth promoting effect, anti-inflammatory effect, antioxidant effect, anti-obesity effect and the like.
참가죽그물바탕말, 주름, 발모, 항염증, 항비만 Participation, wrinkle, hair growth, anti-inflammatory, anti-obesity
Description
본 발명은 참가죽그물바탕말 추출물을 포함하는 조성물에 관한 것이다. 구체적으로 본 발명의 참가죽그물바탕말 추출물은 미백 효과, 주름개선 효과, 면역조절효과, 항산화 효과, 항비만 효과 및 발모 효과가 우수하므로, 본 발명은 참가죽그물바탕말 추출물을 포함하는 화장료 조성물, 약제학적 조성물 및 식품 조성물에 관한 것이다. The present invention relates to a composition comprising the bamboo shoots extract. Particularly, the bamboo bark extract of the present invention is excellent in whitening effect, wrinkle improvement effect, immunomodulatory effect, antioxidant effect, anti-obesity effect and hair growth effect, the present invention is a cosmetic composition comprising the bamboo bark extract extract , Pharmaceutical compositions and food compositions.
사람의 피부색은 피부 내부의 멜라닌(melanin) 농도와 분포에 따라 결정되어진다. 인체 피부의 멜라닌 세포에서 생성되는 멜라닌 색소는 검은 색소와 단백질의 복합 형태를 갖는 페놀계 고분자 물질로서, 자외선으로 발생하는 피부손상을 차단하는 중요한 역할을 하고 있다. 멜라닌 생합성에는 멜라닌 세포에 존재하는 타이로시네이즈의 작용이 가장 중요한 것으로 보고되어 있고, 타이로시네이즈(tyrosinase)는 아미노산의 일종인 티로신(tyrosine)을 멜라닌 중합체 생성의 중간산물인 도파(DOPA), 도파퀴논(dopaquinone)으로 전환함으로써 피부 흑화과정에 핵심적 역할을 수행한다. Human skin color is determined by the concentration and distribution of melanin inside the skin. Melanin pigment produced by melanocytes of human skin is a phenolic polymer having a complex form of black pigment and protein, and plays an important role in blocking skin damage caused by ultraviolet rays. It is reported that the action of tyrosinase in melanocytes is the most important for melanin biosynthesis, and tyrosinase is a type of amino acid tyrosine (DOPA) which is an intermediate of melanin polymer production. It also plays a key role in skin blackening by converting it to dopaquinone.
일반적으로 피부 주름은 피부의 수분 함유량, 콜라겐 함유량 및 외부 환경에 대한 면역 작용 능력 등 여러 가지 요인들의 복합적인 작용에 의해 생성되는 것으로 알려져 있다. 이러한 요인들 중 주름의 형성에 가장 큰 영향을 미치는 것은 콜라겐의 생성량과 콜라겐의 함량을 감소시키는 콜라겐 분해 효소인 콜라게네이즈의 발현량과 활성이다.In general, skin wrinkles are known to be produced by a combination of several factors, such as the skin's water content, collagen content, and the ability to act on the environment. Among these factors, the most important influence on the formation of wrinkles is the expression and activity of collagenase, a collagen degrading enzyme that reduces collagen production and collagen content.
환경오염, 자동차배기가스 등으로 인해 호르몬 불균형 현상이 심화되고 있다. 이로 인해 탈모 발생율이 높아지고, 발생연령도 낮아지고 있고, 피부면역시스템의 부조화가 초래되어 다양한 피부질환 등이 발생하고 있다. 또한 인스턴트 음식, 육류중심의 식생활변화로 어린나이에도 불구하고 비만으로 고통을 받고 있는 인구가 급격히 증가하고 있다.Hormonal imbalance is aggravating due to environmental pollution and automobile exhaust gas. As a result, the incidence of hair loss increases, the age of incidence decreases, and incompatibility of the skin immune system is caused, resulting in various skin diseases. In addition, the population suffering from obesity is rapidly increasing despite the age of children due to the changes in the diet of meat and meat.
따라서, 미적인 차원뿐만 아니라 심각한 사회문제가 되고 있는 여러 가지 현상 즉, 기미 또는 주근깨, 자외선에 의한 주름발생, 비만, 면역불균형, 탈모 등과 같은 현상을 효과적으로 해결할 수 있는 물질개발이 심도 깊게 연구되고 있다. 이에 본 발명자들은 상기와 같은 문제들을 해결하기 위하여 노력하던 중, 참가죽그물바탕말 추출물의 효능을 확인하고 본 발명을 완성하게 되었다.Therefore, the development of materials that can effectively solve various phenomena, such as blemishes or freckles, wrinkles caused by ultraviolet rays, obesity, immune imbalance, hair loss, etc., which are not only aesthetical but also serious social problems, have been studied in depth. The present inventors have been working to solve the above problems, while confirming the efficacy of the participating bamboo nettle extract to complete the present invention.
본 발명의 하나의 목적은 참가죽그물바탕말 추출물을 포함하는 피부 염증, 주름, 피부의 노화 및 발모와 같은 피부 상태(skin conditions)를 개선하기 위한 조성물을 제공하는 것이다.One object of the present invention is to provide a composition for improving skin conditions such as skin inflammation, wrinkles, aging of the skin, and hair growth, comprising the extract of Participatum.
본 발명의 다른 하나의 목적은 참가죽그물바탕말 추출물을 포함하는 발모, 항비만 및 항염증용 약제학적 조성물을 제공하는 것이다.It is another object of the present invention to provide a pharmaceutical composition for hair growth, anti-obesity and anti-inflammatory, which comprises the extract of horseradish spp.
본 발명의 다른 하나의 목적은 참가죽그물바탕말 추출물을 포함하는 항비만용 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide an anti-obesity food composition comprising the extract of the bamboo shoots.
하나의 양태로서, 본 발명은 참가죽그물바탕말 추출물을 포함하는 조성물에 관한 것이다.In one aspect, the present invention relates to a composition comprising the extract of bamboo flakes.
본 발명의 참가죽그물바탕말(Pachydictyon coriaceum)은 갈조식물문(Phaeophyta) 갈조강(Phaeophyceae) 디크티오타목(Dictyotales) 디크티오타과(Dictyotaceae)에 속하는 갈조류를 말한다. 상기 참가죽그물바탕말의 몸은 다소 부채모양으로 펼쳐지고 높이 30~40㎝까지 자라며, 복차상(複叉狀)으로 분기한다. 또한 하부는 짧은 경상부를 이루고 갈색의 모용이 있다. 가지는 대상(帶狀)이며, 폭은 7 내지 15㎜이고, 가장자리는 전연(全緣)이다. 이러한 특징을 가지고 있는 참 가죽그물바탕말과 관련하여 현재까지 이 해양식물의 미백 및 주름 효능 등 피부 조성물로서의 역할은 알려지지 않았다. Participation of the present invention ( Pachydictyon coriaceum ) refers to the brown algae belonging to the Phaeophyta (Phaeophyceae) Diktyotaaceae (Dictyotales) Dicttyotaceae. The participant's body spreads somewhat fan-shaped and grows up to 30-40 cm in height, and branches into a seven-phase image. In addition, the lower part forms a short neck and has a brown hair. The branch is the object, the width is 7 to 15 mm, and the edge is the leading edge. The role of skin composition such as whitening and anti-wrinkle effect of this marine plant is not known with regard to the true leather net horse which has these characteristics.
본 발명의 참가죽그물바탕말 추출물은 통상의 해조류 추출물의 제조 방법에 따라 제조할 수 있다. 구체적으로, 냉침추출법, 온침추출법 또는 열 추출법 등에 의하여 제조할 수 있으며, 통상의 추출기기, 초음파분쇄 추출기 또는 분획기를 이용하여 제조할 수 있다. Participating ginseng extract of the present invention can be prepared according to a conventional method for preparing seaweed extract. Specifically, it may be prepared by a cold extraction method, a hot extraction method or a heat extraction method, it may be prepared using a conventional extraction device, ultrasonic grinding extractor or fractionator.
하나의 구체적 실시로서, 건조되거나 건조되지 않은 참가죽그물바탕말을 분쇄하고, 그 분쇄물에 용매를 10 내지 100배의 중량비로 가하여 침지한 후, 이를 여과 또는 원심 분리하여 상등액을 수득하여 상기 참가죽그물바탕말 추출물을 제조할 수 있다. In one specific embodiment, the dried or undried bamboo grits are pulverized, immersed in the pulverized product by adding a solvent in a weight ratio of 10 to 100 times, and then filtered or centrifuged to obtain a supernatant liquid. Leather net foot extract can be prepared.
다른 하나의 구체적 실시로서, 참가죽그물바탕말에 물 또는 유기 용매를 가하고, 70℃ 이상, 바람직하게는 80℃ 이상, 보다 바람직하게는 90℃ 이상의 온도에서 1 시간 이상, 바람직하게는 2 시간 이상, 보다 바람직하게는 4 시간 이상 가열하고 가열된 추출물을 여과하여 제조할 수 있다.As another specific embodiment, water or an organic solvent is added to the participating bamboo grass, and at least 70 hours, preferably at least 80 degrees Celsius, more preferably at least 90 degrees Celsius, at least 1 hour, preferably at least 2 hours. More preferably 4 hours or more and the heated extract can be produced by filtration.
상기 추출물을 제조함에 있어, 사용되는 추출용매는 이로 한정되는 것은 아니지만, 물, 유기 용매 또는 이들의 혼합 용매일 수 있다. 상기 유기 용매는 예를 들어, 메탄올, 에탄올, 이소프로탄올, 부탄올 등의 알콜, 에틸렌, 아세톤, 에테르, 헥산, 클로로포름, 에틸아세테이트, DMF (N,N-디메틸포름아미드), DMSO (디메틸설폭사이드) 및 이들의 혼합물이다. 바람직하게는 추출 용매는 물 또는 에탄올일 수 있다. In preparing the extract, the extraction solvent used is not limited thereto, but may be water, an organic solvent or a mixed solvent thereof. The organic solvent is, for example, alcohols such as methanol, ethanol, isoprotanol, butanol, ethylene, acetone, ether, hexane, chloroform, ethyl acetate, DMF (N, N-dimethylformamide), DMSO (dimethylsulfoxide ) And mixtures thereof. Preferably the extraction solvent may be water or ethanol.
상기 용매로 추출한 추출물은 이후, 이로 한정되는 것은 아니지만, 헥산, 메틸렌클로라이드, 아세톤, 에틸아세테이트, 에틸에테르, 클로로포름, 물 및 이들의 혼합물로 이루어진 군으로부터 선택된 용매로 분획과정을 더욱 실시할 수 있다. 상기 분획용매는 바람직하게는 에탄올 수용액, 물, 에틸아세테이트 및 클로로포름으로 이루어진 군에서 선택된 1 이상일 수 있다. The extract extracted with the solvent is, but is not limited thereto, and may be further fractionated with a solvent selected from the group consisting of hexane, methylene chloride, acetone, ethyl acetate, ethyl ether, chloroform, water and mixtures thereof. The fractional solvent may be preferably at least one selected from the group consisting of aqueous ethanol, water, ethyl acetate and chloroform.
상기 제조된 추출물 또는 상기 분획과정을 수행하여 수득한 분획물은 이후 여과하거나 농축 또는 건조과정을 수행하여 용매를 제거할 수 있으며, 여과, 농축 및 건조를 모두 수행할 수 있다. 구체적으로 상기 여과는 여과지를 이용하거나 감압여과기를 이용할 수 있으며, 상기 농축은 감압 농축기, 일례로 회전 증발기를 이용하여 감압 농축할 수 있으며, 상기 건조는 일례로 동결건조법으로 수행할 수 있다.The prepared extract or the fraction obtained by performing the fractionation process can be filtered or concentrated or dried to remove the solvent, it can be carried out both filtration, concentration and drying. Specifically, the filtration may be performed using a filter paper or a reduced pressure filter, the concentration may be concentrated under reduced pressure using a reduced pressure concentrator, for example, a rotary evaporator, and the drying may be performed by, for example, a lyophilization method.
따라서 본 발명에서 사용된 참가죽그물바탕말 추출물은 상기 제조된 추출물 또는 분획물을 포함하며, 또한 상기 추출물 또는 분획물을 농축 및 동결건조를 통하여 수분을 완전히 제거시킨 것일 수 있으며, 상기 수분을 완전히 제거시킨 갈조류 추출물 또는 분획물은 분말 형태로 사용하거나 상기 분말을 증류수 또는 통상의 용매에 녹여 사용할 수 있다.Therefore, the participated porridge root extract used in the present invention includes the prepared extract or fraction, and the extract or fraction may be one which completely removes moisture by concentrating and lyophilizing and completely removing the moisture. Brown algae extract or fractions may be used in powder form, or the powder may be used after being dissolved in distilled water or a common solvent.
본 발명의 참가죽그물바탕말 추출물은 세포 내 타이로시네이즈의 활성을 억제함으로써 멜라닌 생성을 억제하는 우수한 미백효과를 나타내며, 안정성이 높고, 시간 경과에 따른 성분 함량의 변화가 거의 없으며, 피부 자극 유발 등의 부작용이 거의 없다. Participating ginseng extract of the present invention exhibits an excellent whitening effect of inhibiting melanin production by inhibiting the activity of intracellular tyrosinase, has high stability, almost no change in the component content over time, and skin irritation. There are few side effects such as induction.
또한, 본 발명의 참가죽그물바탕말 추출물은 콜라게네이즈 활성 억제 및 콜라겐 합성의 촉진 등의 분자적 기전을 통하여 우수한 주름 개선 효능을 발휘한다.In addition, the participated bark nettle extract of the present invention exhibits an excellent wrinkle improvement effect through molecular mechanisms such as inhibiting collagenase activity and promoting collagen synthesis.
또한, 본 발명의 참가죽그물바탕말 추출물은 발모 촉진 효과가 우수하다. 구체적 실시에서 시판 중인 발모제와 비교한 결과, 본 발명의 참가죽그물바탕말 추출물의 발모 효과가 우수함을 알 수 있었다. 본원에서는 편의상 “발모 촉진”을 “탈모 방지” 또는 “육모 촉진”과 혼용하여 사용한다.In addition, the porridge extract of the present invention is excellent in hair growth promoting effect. As a result of comparison with a commercially available hair regrowth in a specific implementation, it was found that the hair growth effect of the participating bamboo bark horse extract of the present invention is excellent. For convenience, the term "promoting hair growth" is used interchangeably with "preventing hair loss" or "promoting hair growth".
또한, 본 발명의 참가죽그물바탕말 추출물은 우수한 자유라디칼 제거 효과로 인한 항산화 효과가 우수하다. 많은 질환상태와 자유라디칼 손상과의 상관관계는 널리 입증되어 있으며 효소, 이온채널, 구조 단백질 및 막지질을 포함하는 많은 세포 구성성분이 반응성 자유 라디칼 종에 대한 잠재적인 표적물이다(Rice-Evans C, Mol Aspects of Med 13(1):1-111(1992)). 상기 잠재적인 표적물과 자유 라디칼의 반응은 특정범위의 세포기능을 손상시켜 병리학적 변화를 유발하여 궁극적으로 세포를 사멸시킨다. 또한, 생리학적인 산화에 의해 다양한 질병이 야기되는 것은, 미국 특허 제 5,750,351호, 제5,773,209호, 제5,773,231호 및 제5,846,959호에 개시되어 있다. 그 질환의 예로는 아테롬성 동맥경화증, 관상동맥질환, 심장동맥 재협착, 재관류 손상, 파키슨병 또는 알츠하이머 질환과 같은 신경변성 질환, 뇌졸중, 암, 노화, 심혈관 질환, 골다공증, 중추신경계 장애, 말초혈관 질환 및 호흡곤란 등이 있다. 따라서, 본 발명의 참가죽그물바탕말 추출물은 항산화 효과가 우수 하므로 상기한 바와 같은 질환의 예방 및 치료 목적으로 유용하게 사용할 수 있다. In addition, the porridge extract of the present invention is excellent in the antioxidant effect due to the excellent free radical removal effect. The correlation between many disease states and free radical damage is well established and many cellular components, including enzymes, ion channels, structural proteins and membrane lipids, are potential targets for reactive free radical species (Rice-Evans C). , Mol Aspects of Med 13 (1): 1-111 (1992). The reaction of these potential targets with free radicals impairs a range of cellular functions leading to pathological changes that ultimately kill cells. In addition, various diseases caused by physiological oxidation are disclosed in US Pat. Nos. 5,750,351, 5,773,209, 5,773,231, and 5,846,959. Examples of the disease include atherosclerosis, coronary artery disease, coronary artery restenosis, reperfusion injury, neurodegenerative diseases such as Parkinson's disease or Alzheimer's disease, stroke, cancer, aging, cardiovascular disease, osteoporosis, central nervous system disorders, peripheral vascular disease And difficulty breathing. Therefore, the bamboo bark extract of the present invention has an excellent antioxidant effect and can be usefully used for the prevention and treatment of diseases as described above.
또한, 본 발명의 참가죽그물바탕말 추출물은 COX 활성을 억제하는 효과가 있으므로 항염증 효과를 가진다.In addition, the bamboo bark extract of the present invention has an anti-inflammatory effect because it has the effect of inhibiting COX activity.
또한, 본 발명의 참가죽그물바탕말 추출물은 비만을 억제하는 효과를 가진다.In addition, the porridge extract of the present invention has the effect of inhibiting obesity.
하나의 구체적 양태로서, 본 발명은 상기 참가죽그물바탕말 추출물을 포함하는 피부 상태 개선용 화장료 조성물로서, 상기 피부 상태는 피부 염증, 주름, 피부의 노화 및 발모 중의 어느 하나 이상인 피부 상태 개선용 화장료 조성물에 관한 것이다.As one specific embodiment, the present invention is a cosmetic composition for improving the skin condition comprising the participating moth extract, wherein the skin condition is any one or more of skin inflammation, wrinkles, aging and regrowth of skin cosmetics It relates to a composition.
본 발명에 있어서, “피부 상태(skin condition)”는 피부 염증, 주름, 피부의 노화 및 발모를 포함하는 의미이다. In the present invention, "skin condition" means skin inflammation, wrinkles, aging of the skin and hair growth.
본 발명의 참가죽그물바탕말 추출물은 상기 조성물의 총 중량에 대해 0.01 내지 20 중량%, 바람직하게는 0.01 내지 10 중량%, 보다 바람직하게는 0.01 내지 5의 중량%의 양으로 포함된다.Participants of the present invention is included in an amount of 0.01 to 20% by weight, preferably 0.01 to 10% by weight, more preferably 0.01 to 5% by weight relative to the total weight of the composition.
본 발명의 화장료 조성물에 포함되는 성분은 유효 성분으로서의 참가죽그물바탕말 추출물 이외에 화장료 조성물에 통상적으로 이용되는 성분들을 포함한다. 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 및 담체를 포함한다. 또한, 상기 화장료 조성물은 그 효과를 증진시키기 위하여 피부 흡수 촉진 물질을 추가로 포함할 수 있다.The components included in the cosmetic composition of the present invention include components conventionally used in cosmetic compositions in addition to the participating bamboo grass extract as an active ingredient. Conventional adjuvants such as, for example, antioxidants, stabilizers, solubilizers, vitamins, pigments and flavorings, and carriers. In addition, the cosmetic composition may further include a skin absorption promoting substance to enhance the effect.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화될 수 있으나, 이에 한정되는 것은 아니다. 보다 상세하게는, 유연 화장수, 영양 화장수, 영양 크림, 마사지 크림, 에센스, 아이 크림, 클렌징 크림, 클렌징 포옴, 클렌징 워터, 팩, 스프레이 또는 파우더의 제형으로 제조될 수 있다.The cosmetic composition of the present invention may be prepared in any formulation commonly prepared in the art, for example, solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing , Oils, powder foundations, emulsion foundations, wax foundations and sprays, and the like, but are not limited thereto. More specifically, it can be manufactured in the form of a soft lotion, a nutritional lotion, a nutritional cream, a massage cream, an essence, an eye cream, a cleansing cream, a cleansing foam, a cleansing water, a pack, a spray or a powder.
본 발명의 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation of the present invention is a paste, cream or gel, animal oils, vegetable oils, waxes, paraffins, starches, trachants, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicas, talc or zinc oxide may be used as carrier components. Can be.
본 발명의 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.In the case where the formulation of the present invention is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component. Especially, in the case of a spray, a mixture of chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
본 발명의 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸 글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation of the present invention is a solution or emulsion, a solvent, solubilizer or emulsifier is used as the carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1 Fatty acid esters of, 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan.
본 발명의 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the formulation of the present invention is a suspension, liquid carrier diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystals Soluble cellulose, aluminum metahydroxy, bentonite, agar or tracant and the like can be used.
본 발명의 제형이 계면-활성제 함유 클린징인 경우에는 담체 성분으로서 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세리드, 지방산 디에탄올아미드, 식물성 유, 라놀린 유도체 또는 에톡실화 글리세롤 지방산 에스테르 등이 이용될 수 있다.When the formulation of the present invention is a surfactant-containing cleansing, the carrier component is an aliphatic alcohol sulfate, an aliphatic alcohol ether sulfate, a sulfosuccinic acid monoester, isethionate, an imidazolinium derivative, a methyltaurate, a sarcosinate, a fatty acid amide. Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters and the like can be used.
다른 하나의 구체적 양태로서, 본 발명은 참가죽그물바탕말 추출물을 포함하는 발모용, 항비만용 및 항염증용 약제학적 조성물에 관한 것이다.In another specific embodiment, the present invention relates to a pharmaceutical composition for hair growth, anti-obesity and anti-inflammatory, comprising the extract of Participating Bacteria.
본 발명의 참가죽그물바탕말 추출물은 상기 약제학적 조성물의 총 중량에 대해 0.01 내지 20 중량%, 바람직하게는 0.01 내지 10 중량%, 보다 바람직하게는 0.01 내지 5의 중량%의 양으로 포함된다.Participants of the present invention is included in an amount of 0.01 to 20% by weight, preferably 0.01 to 10% by weight, more preferably 0.01 to 5% by weight relative to the total weight of the pharmaceutical composition.
본 발명의 약제학적 조성물은 참가죽그물바탕말 추출물 외에 추가로 발모촉진, 비만 억제 및/또는 항염증 효과를 나타내는 유효성분을 1종 이상 함유할 수 있다.The pharmaceutical composition of the present invention may further contain at least one active ingredient exhibiting hair growth promoting, obesity inhibiting and / or anti-inflammatory effect in addition to the participating bamboo grass extract.
또한, 본 발명의 약제학적 조성물은 약제학적 조성물의 제조에 통상적으로 사용되는 약제학적으로 허용되는 담체를 더 포함할 수 있다. 본 발명의 약제학적 조성물에 포함되는 약제학적으로 허용되는 담체는 제제 시에 통상적으로 이용되는 것으로서, 락토스, 덱스트로스, 수크로스, 솔비톨, 만니톨, 전분, 아카시아 고무, 인산 칼슘, 알기네이트, 젤라틴, 규산 칼슘, 미세결정성 셀룰로스, 폴리비닐피롤리돈, 셀룰로스, 물, 시럽, 메틸 셀룰로스, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 활석, 스테아르산 마그네슘 및 미네랄 오일 등을 포함하나, 이에 한정되는 것은 아니다. 본 발명의 약제학적 조성물은 상기 성분들 이외에 윤활제, 습윤제, 감미제, 향미제, 유화제, 현탁제, 보존제등을 추가로 포함할 수 있다. 적합한 약제학적으로 허용되는 담체 및 제제는 Remington's Pharmaceutical Sciences (19th ed., 1995)에 상세히 기재되어 있다.In addition, the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier conventionally used in the preparation of the pharmaceutical composition. Pharmaceutically acceptable carriers included in the pharmaceutical compositions of the present invention are those commonly used in the preparation, such as lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, Calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like It doesn't happen. The pharmaceutical composition of the present invention may further include lubricants, wetting agents, sweeteners, flavoring agents, emulsifiers, suspending agents, preservatives and the like in addition to the above components. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Sciences (19th ed., 1995).
본 발명의 약제학적 조성물은 쥐, 생쥐, 가축, 인간 등의 포유동물에 경구 또는 비경구 등의 다양한 경로로 투여할 수 있으며, 예컨대 경구, 직장 또는 정맥, 근육, 피하, 자궁내 경막 또는 뇌혈관내 주사에 의해 투여할 수 있다. 바람직하게는 비경구 투여 중 경피투여, 보다 바람직하게는 도포에 의한 국부 투여(topical application) 방식으로 적용된다.The pharmaceutical composition of the present invention can be administered to mammals such as rats, mice, livestock, humans by various routes such as oral or parenteral, such as oral, rectal or intravenous, muscle, subcutaneous, intrauterine dura or cerebrovascular vessels. It can be administered by internal injection. It is preferably applied in the form of topical application during parenteral administration, more preferably by application.
본 발명의 약제학적 조성물의 적합한 투여량은 제제화 방법, 투여 방식, 환자의 연령, 체중, 성, 병적 상태, 음식, 투여 시간, 투여 경로, 배설 속도 및 반응 감응성과 같은 요인들에 의해 다양하게 처방될 수 있다. 본 발명의 약제학적 조성물의 투여량은, 경구형 제형인 경우 성인 기준으로 0.1-100 ㎎/kg 의 양을 1일 1회 내지 수회 투여할 수 있으며, 외용제인 경우에는 성인 기준으로 1일당 1.0 내지 3.0 ml의 양으로 1일 1 내지 5회 도포하여 1개월 이상 계속 하는 것이 좋다. 다만, 상기 투여량은 본 발명의 범위를 한정하는 것은 아니다.Suitable dosages of the pharmaceutical compositions of the present invention may vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to response of the patient. Can be. The dosage of the pharmaceutical composition of the present invention may be administered once or several times a day in an oral dosage form of 0.1-100 mg / kg on an adult basis. It is recommended to apply 1 to 5 times a day in an amount of 3.0 ml to continue for 1 month or more. However, the dosage does not limit the scope of the present invention.
본 발명의 약제학적 조성물은 당해 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 용이하게 실시할 수 있는 방법에 따라, 약제학적으로 허용되는 담체 및/또는 부형제를 이용하여 제제화함으로써 단위 용량 형태로 제조되거나 또는 다용량 용기 내에 내입시켜 제조될 수 있다. 이때 제형은 산제, 과립제, 정제, 캅셀제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 연고, 크림 등의 외용제, 좌제 및 멸균 주사용액 등을 비롯하여 약제학적 제제에 적합한 어떠한 형태로든 사용할 수 있으며, 분산제 또는 안정화제를 추가적으로 포함할 수 있다.The pharmaceutical compositions of the present invention may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or may be prepared by incorporation into a multi-dose container. The formulation may be used in any form suitable for pharmaceutical preparations, including powders, granules, tablets, capsules, suspensions, emulsions, syrups, oral formulations such as aerosols, external preparations such as ointments, creams, suppositories, and sterile injectable solutions. It may further comprise a dispersant or stabilizer.
또한, 본 발명의 약제학적 조성물은 발모 촉진, 비만 억제 및 항염증을 위하여 단독으로, 또는 수술, 방사선 치료, 호르몬 치료, 화학 치료 및 생물학적 반응 조절제를 사용하는 방법들과 병용하여 사용할 수 있다.In addition, the pharmaceutical compositions of the present invention can be used alone or in combination with methods using surgery, radiation therapy, hormonal therapy, chemotherapy and biological response modifiers for promoting hair growth, inhibiting obesity and anti-inflammatory.
다른 하나의 구체적 양태로서, 다른 하나의 양태로서, 본 발명은 참가죽그물바탕말 추출물을 포함하는 항비만용 식품 조성물에 관한 것이다.As another specific aspect, as another aspect, this invention relates to the food composition for anti-obesity which contains the extract of horseradish root.
본 발명의 참가죽그물바탕말 추출물은 상기 식품 조성물의 총 중량에 대해 0.01 내지 20 중량%, 바람직하게는 0.01 내지 10 중량%, 보다 바람직하게는 0.01 내지 5의 중량%의 양으로 포함된다.Participants of the present invention is included in an amount of 0.01 to 20% by weight, preferably 0.01 to 10% by weight, more preferably 0.01 to 5% by weight relative to the total weight of the food composition.
본 발명의 참가죽그물바탕말 추출물은 비만 억제를 목적으로 건강식품에 첨가될 수 있다. 본 발명의 참가죽그물바탕말 추출물을 식품 첨가물로 사용할 경우, 상기 참가죽그물바탕말 추출물을 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합양은 사용 목적(예방, 건강 또는 치료적 처치)에 따라 적합하게 결정될 수 있다. 일반적으로, 식품 또는 음료의 제조시에 본 발명의 조성물은 원료에 대하여 15중량% 이하, 바람직하게는 10 중량% 이하의 양으로 첨가된다. 그러나, 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 범위 이하일 수 있으며, 안전성 면에서 아무런 문제가 없기 때문에 유효성분은 상기 범위 이상의 양으로도 사용될 수 있다.Participants of the present invention may be added to health food for the purpose of inhibiting obesity. When using the ginseng extract of the present invention as a food additive, it can be added as it is, or used together with other food or food ingredients, can be appropriately used in accordance with conventional methods. The mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment). Generally, in the preparation of food or beverages, the composition of the present invention is added in an amount of up to 15% by weight, preferably up to 10% by weight relative to the raw material. However, in the case of long-term intake for the purpose of health and hygiene or for the purpose of health control, it may be below the above range, and the active ingredient may be used in an amount above the above range because there is no problem in terms of safety.
상기 식품의 종류에는 특별한 제한은 없다. 상기 물질을 첨가할 수 있는 식품의 예로는 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기 타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 및 비타민 복합제 등이 있으며, 통상적인 의미에서의 건강식품을 모두 포함한다.There is no particular limitation on the kind of food. Examples of the food to which the substance may be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, ice cream, various soups, beverages, tea, and drinks. Alcoholic beverages and vitamin complexes, and includes all of the health foods in the conventional sense.
본 발명의 건강음료 조성물은 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상술한 천연 탄수화물은 포도당, 과당과 같은 모노사카라이드, 말토스, 슈크로스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 천연 감미제나, 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100㎖ 당 일반적으로 약 0.01 내지 0.4g, 바람직하게는 약 0.02 내지 0.03g 이다.The health beverage composition of the present invention may contain various flavors or natural carbohydrates as an additional ingredient such as ordinary beverages. The natural carbohydrates described above may be used as monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, and natural sweeteners such as dextrin and cyclodextrin, and synthetic sweeteners such as saccharin and aspartame. . The proportion of the natural carbohydrate is generally about 0.01 to 0.4 g, preferably about 0.02 to 0.03 g per 100 ml of the composition of the present invention.
상기 외에 본 발명의 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 조성물은 천연 과일쥬스, 과일쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 크게 중요하진 않지만 본 발명의 조성물 100중량부 당 0.01 내지 0.1 중량부의 범위에서 선택되는 것이 일반적이다.In addition to the above, the composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, And a carbonation agent used for the carbonated beverage. In addition, the composition of the present invention may contain a pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components can be used independently or in combination. The proportion of such additives is not critical but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the composition of the present invention.
한편, 본 발명의 구체적 실시에서 참가죽그물바탕말 추출물에 대한 피부누적 자극시험 결과 참가죽그물바탕말 추출물은 천연물질로서 인체에 무해한 물질임이 밝혀졌다. 따라서 본 발명의 참가죽그물바탕말 추출물은 독성 및 부작용이 거의 없으므로 장기간 사용 시에도 안심하고 사용할 수 있으며, 특히 상기한 바와 같은 화장료, 약품 및 식품 조성물에 안전하게 적용할 수 있다.On the other hand, in the specific practice of the present invention, the skin accumulation stimulation test results for the participating bamboo grass extract extract was found to be a natural substance harmless to the human body. Therefore, the bamboo shoots extract of the present invention has little toxicity and side effects, so that it can be used safely even when used for a long time, and in particular, it can be safely applied to cosmetics, drugs and food compositions as described above.
본 발명의 참가죽그물바탕말 추출물은 기존의 피부 미백제로 사용되고 있는 알부틴에 비해 세포내 타이로시네이즈의 활성을 억제함으로서 멜라닌 생성을 억제하는 우수한 미백 효과, 콜라게네이즈 활성 억제 및 콜라겐 합성의 촉진 등의 분자적 기전을 통하여 우수한 주름 개선 효능, 항염증 효과, 발모 촉진 효과, 항산화 효과 및 항비만 효과를 가진다. 또한, 본 발명의 참가죽그물바탕말 추출물은 세포독성 및 피부 부작용이 없어 화장료, 약품 및 식품에 안전하게 적용할 수 있다.Participating bamboo extract of the present invention has excellent whitening effect, inhibits collagenase activity and promotes collagen synthesis by inhibiting melanin production by inhibiting the activity of intracellular tyrosinase compared to arbutin, which is used as a conventional skin whitening agent. Through molecular mechanisms such as excellent wrinkle improvement, anti-inflammatory effect, hair growth promoting effect, antioxidant effect and anti-obesity effect. In addition, the porridge extract of the present invention can be safely applied to cosmetics, drugs and foods because there is no cytotoxicity and skin side effects.
이하, 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로서, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자에게 있어서 자명할 것이다. Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, and the scope of the present invention is not limited by these examples in accordance with the gist of the present invention to those skilled in the art. Will be self-evident.
실시예 1 : 참가죽그물바탕말 추출물의 제조Example 1 Preparation of Participation Grain Extract
1-1. 물 가용 추출물의 제조1-1. Preparation of Water Soluble Extract
완전 건조시킨 참가죽그물바탕말 1kg을 증류수 3ℓ에 넣고 냉각 콘덴서가 달린 추출기에서 15 내지 37℃에서 14일간 추출하였다. 그 추출물을 400 메쉬 여과포로 여과하고, 5 내지 15℃에서 7일간 방치하여 숙성시킨 후 와트만 2번 여과지로 여과하였다. 이들 식물 추출물을 냉각 콘덴서가 달린 증류장치에서 감압 농축하여 각각 29g, 30g, 29g(건조중량)을 얻었다.1 kg of fully dried bamboo sprouts was placed in 3 l of distilled water, and extracted in a extractor equipped with a cooling condenser at 15 to 37 ° C. for 14 days. The extract was filtered through a 400 mesh filter cloth, left to mature at 5 to 15 ° C. for 7 days, and then filtered using Whatman No. 2 filter paper. These plant extracts were concentrated under reduced pressure in a distillation apparatus equipped with a cooling condenser to obtain 29 g, 30 g, and 29 g (dry weight), respectively.
1-2. 에탄올 가용 추출물의 제조1-2. Preparation of Ethanol Soluble Extract
완전 건조시킨 참가죽그물바탕말 1kg을 에탄올 3ℓ에 넣고 냉각 콘덴서가 달린 추출기에서 15 내지 37℃에서 14일간 추출하였다. 그 추출물을 400 메쉬 여과포로 여과하고, 5 내지 15℃에서 7일간 방치하여 숙성시킨 후 와트만 2번 여과지로 여과하였다. 이들 식물 추출물을 냉각 콘덴서가 달린 증류장치에서 감압 농축하여 각각 31g, 39g, 37g(건조중량)을 얻었다.1 kg of fully dried bamboo sprouts were placed in 3 l of ethanol and extracted for 14 days at 15 to 37 ° C. in an extractor equipped with a cooling condenser. The extract was filtered through a 400 mesh filter cloth, left to mature at 5 to 15 ° C. for 7 days, and then filtered using Whatman No. 2 filter paper. These plant extracts were concentrated under reduced pressure in a distillation apparatus equipped with a cooling condenser to obtain 31 g, 39 g, and 37 g (dry weight), respectively.
1-3. 메탄올 가용 추출물의 제조1-3. Preparation of Methanol Soluble Extract
완전 건조시킨 참가죽그물바탕말 1kg을 메탄올 3ℓ에 넣고 냉각 콘덴서가 달린 추출기에서 15 내지 37℃에서 14일간 추출하였다. 그 추출물을 400 메쉬 여과포로 여과하고, 5 내지 15℃에서 7일간 방치하여 숙성시킨 후 와트만 2번 여과지로 여과하였다. 이들 식물 추출물을 냉각 콘덴서가 달린 증류장치에서 감압 농축하여 각각 38g, 41g, 39g(건조중량)을 얻었다.1 kg of fully dried bamboo flakes were placed in 3 l of methanol and extracted for 14 days at 15 to 37 ° C. in an extractor equipped with a cooling condenser. The extract was filtered through a 400 mesh filter cloth, left to mature at 5 to 15 ° C. for 7 days, and then filtered using Whatman No. 2 filter paper. These plant extracts were concentrated under reduced pressure in a distillation apparatus equipped with a cooling condenser to obtain 38 g, 41 g, and 39 g (dry weight), respectively.
실시예 2 : 참가죽그물바탕말 추출물에 의한 멜라닌 생성 억제효과 측정Example 2 measurement of melanin production inhibitory effect
쥐의 색소세포(B16 melanoma cells)(한국세포주은행)를 이용하여 참가죽그물바탕말 추출물에 의한 멜라닌 생성 억제효과를 측정하였으며, 이를 멜라닌 생성을 억제하는 것으로 알려진 알부틴에 의한 멜라닌 생성 억제효과와 비교하였다.B16 melanoma cells (Korea Cell Line Bank) were used to measure the inhibitory effect of melanin production by the extracts of the bark horseweed and compared with the inhibitory effect of melanin production by arbutin known to inhibit melanin production. It was.
본 실험은 뮤라인 멜로노마(murine melanoma)(B-16 F10) 세포(한국세포주은행)를 10%의 FBS(fetal bovine serum)가 함유된 DMEM 배지로 6-웰 플레이트에 웰 당 1× 105 개로 접종한 후, 5% CO2 및 37℃하에서 세포가 웰 바닥에 약 80% 이상 부착될 때까지 배양하였다. 배양 후 배지를 제거하고 알부틴(Arbutin, Sigma)100 ppm 및 실시예 1-2의 참가죽그물바탕말 추출물을 세포 독성이 없는 10 ppm, 100 ppm 및 500 ppm의 농도로 희석된 DMEM 배지로 교체하고, 5% CO2, 37 ℃에서 3일간 배양하였다. 그 후 배지를 제거하고 수집한 세포를 PBS(phosphate buffer saline)로 세척하고, 이것을 트립신으로 처리하여 세포를 회수하였다. 회수된 세포는 헤마토사이토미터(hematocytometer, Tiefe Depth Profondeur 0.100 mm, Paul Marienfeld GmbH & Co. KG, 독일)를 이용하여 세포수를 측정하고, 5,000 내지 10,000 rpm으로 10분간 원심분리한 다음 상층액을 제거하여 펠릿을 얻었다. 이 세포 펠릿을 60℃에서 건조한 후, 10% DMSO가 함유된 1 M 수산화나트륨액 100 ㎕를 넣고 60℃ 항온조에서 세포내 멜라닌을 얻었다. 이 액을 가지고 마이크로플레이트 리더(microplate reader)(Bio-Tek ELx8081U, 미국)로 490 nm에서 흡광도를 측정하여 세포 일정 수당 멜라닌 양을 구하였다. 그 결과를 하기 표 1에 나타내었다.In this experiment, murine melanoma (B-16 F10) cells (Korea Cell Line Bank) were used in DMEM medium containing 10% fetal bovine serum (FBS) in a 6-well plate at 1 × 10 5 per well. After inoculation with dogs, the cells were incubated at 5% CO 2 and 37 ° C until at least about 80% were attached to the bottom of the well. After incubation, the medium was removed, and 100 parts of arbutin (Arigin, Sigma) and the participant extract of Example 1-2 were replaced with DMEM medium diluted to 10 ppm, 100 ppm and 500 ppm of non-cytotoxicity. , 5% CO 2 , was incubated for 3 days at 37 ℃. Thereafter, the medium was removed, and the collected cells were washed with PBS (phosphate buffer saline), which was treated with trypsin to recover the cells. The recovered cells were measured by using a hematocytometer (Tiefe Depth Profondeur 0.100 mm, Paul Marienfeld GmbH & Co. KG, Germany) to measure the cell number, centrifuged at 5,000 to 10,000 rpm for 10 minutes, and then the supernatant was removed. It was removed to obtain pellets. The cell pellet was dried at 60 ° C., and then 100 μl of 1 M sodium hydroxide solution containing 10% DMSO was added to obtain intracellular melanin in a 60 ° C. thermostat. Using this solution, the absorbance was measured at 490 nm using a microplate reader (Bio-Tek ELx8081U, USA) to determine the amount of melanin per cell. The results are shown in Table 1 below.
상기 표 1에 기재된 바와 같이, 참가죽그물바탕말 추출물은 알부틴 보다 멜라닌 생성 억제율이 높으며, 또한 참가죽그물바탕말 추출물의 처리 농도를 증가시킬수록 멜라닌 생성 억제율이 높아짐을 알 수 있었다.As shown in Table 1, it was found that the participant extract was higher in melanin production than arbutin, and the higher the treatment concentration of the participant extract was higher in melanin production.
실시예 3 : 참가죽그물바탕말 추출물에 의한 세포내 타이로시네이즈 활성억제 효과 측정Example 3 Measurement of Inhibitory Effects of Intracellular Tyrosinase Activity by Participated Extracts
쥐의 색소세포(B16 melanoma cells)를 이용하여 참가죽그물바탕말 추출물에 의한 멜라닌 생성 억제효과를 측정하고, 이를 멜라닌 생성을 억제하는 것으로 알려진 알부틴에 의한 세포내 타이로시네이즈 활성 억제효과와 비교하였다.Using melanoma cells (B16 melanoma cells) to measure the inhibitory effect of melanin production by the extracts of the bark horseweed, and compared with the inhibitory effect of intracellular tyrosinase activity by arbutin known to inhibit melanin production It was.
본 실험은 뮤라인 멜라노마(murine melanoma)(B-16 F1) 세포를 10%의 FBS (fetal bovine serum)가 함유된 DMEM 배지로 6-웰 플레이트에 웰 당 1× 105 개로 접종한 후 5% CO2, 37℃에서 세포가 웰 바닥에 약 80 % 이상 부착될 때까지 배양하였다. 배양 후 배지를 제거하고 알부틴(Arbutin, Sigma) 100 ppm 및 실시예 1-2의 참가죽그물바탕말 추출물을 세포 독성이 없는 10 ppm, 100 ppm 및 500 ppm의 농도로 희석된 DMEM배지로 교체하고, 5% CO2, 37 ℃에서 3일간 배양하였다. 그 후 배지를 제거하고 수집한 세포를 PBS(phosphate buffer saline)로 세척하고, 이것을 트립신으로 처리하여 세포를 회수하였다. 회수된 세포는 헤마토사이토미터(hematocytometer)를 이용하여 세포수를 측정한 후 5,000 내지 10,000 rpm으로 10분간 원심분리한 다음 상층액을 제거하여 펠릿을 얻었다. 이 세포 펠릿을 용해 완충액을 이용하여 분쇄한 후, 12,000rpm으로 10분간 원심분리하여 상층액을 수집하였다. 이 액을 가지고 마이크로플레이트 리더(microplate reader)로 492 nm에서 흡광도를 측정하여 세포 일정 수당 타이로시네이즈 활성을 구하였다. 그 결과를 하기 표 2에 나타내었다.This experiment was performed by inoculating murine melanoma (B-16 F1) cells in 6-well plates at 1 × 10 5 per well in DMEM medium containing 10% FBS (fetal bovine serum). The cells were incubated at% CO 2 , 37 ° C. until the cells adhered at least about 80% to the bottom of the well. After incubation, the medium was removed, and 100 parts of arbutin (Arigin, Sigma) and the participant extract of Example 1-2 were replaced with DMEM medium diluted to 10 ppm, 100 ppm and 500 ppm of non-cytotoxicity. , 5% CO 2 , was incubated for 3 days at 37 ℃. Thereafter, the medium was removed, and the collected cells were washed with PBS (phosphate buffer saline), which was treated with trypsin to recover the cells. The recovered cells were measured by using a hematocytometer, and then centrifuged at 5,000 to 10,000 rpm for 10 minutes, and then the supernatant was removed to obtain pellets. The cell pellet was pulverized using lysis buffer, and then centrifuged at 12,000 rpm for 10 minutes to collect supernatant. Using this solution, absorbance at 492 nm was measured with a microplate reader to determine cell-specific allowance tyrosinase activity. The results are shown in Table 2 below.
상기 표 2에 기재된 바와 같이, 참가죽그물바탕말 추출물이 알부틴보다 세포내 타이로시네이즈 억제율이 높음을 알 수 있었다. 또한, 참가죽그물바탕말 추출물의 타이로시네이즈 활성 억제 정도는 농도-의존적이라는 것을 알 수 있었다.As shown in Table 2, it was found that the participant extract was higher in intracellular tyrosinase inhibition rate than arbutin. In addition, it was found that the degree of inhibition of tyrosinase activity of the participating bamboo bark horse extract was concentration-dependent.
실시예 4 : 동물수준에서의 미백 효과 평가Example 4 Evaluation of Whitening Effect at Animal Level
사람과 유사하게 자외선에 의해 색소침착이 생긴다고 알려진 갈색 몰모토(Tortoiseshell guinea pigs; Brown guinea pigs, Charles River Laboratories, Inc.)를 사용하여 참가죽그물바탕말 추출물에 의한 미백효과를 측정하였다. Similar to humans, the whitening effect of participating moth extract was measured using brown malmoto (Tortoiseshell guinea pigs; Brown guinea pigs, Charles River Laboratories, Inc.), which is known to cause pigmentation by ultraviolet rays.
상기 갈색 몰모토에서 자외선(UV)에 의한 색소침착을 유발하기 위하여, 갈색 몰모토 배위의 털을 제거한 피부에 3 X 3 cm2의 정방형 창문이 뚫린 차광용 알루미늄 호일을 접착시킨 후, SE lamp(파장 290-320 nm, 도시바)로 자외선을 조사하였다(총 조사 에너지량 = 1350 mJ/cm2). 자외선 조사 후 알루미늄 호일을 벗겨내고 아래와 같은 방법으로 시료(참가죽그물바탕말 추출물 및 알부틴)를 도포하였다. 자외선 조사 후 2-3일 후에 색소침착이 나타났으며, 약 2주 후에 최고에 도달하였고, 이 때부터 각 시료를 도포하였다.In order to cause pigmentation due to ultraviolet (UV) in the brown molemoto, a light shielding aluminum foil having a square window of 3 × 3 cm 2 is adhered to the skin from which the hair of the brown molemoto coordination is removed, and then SE lamp ( Ultraviolet rays were irradiated with a wavelength of 290-320 nm (Toshiba) (total amount of irradiation energy = 1350 mJ / cm 2 ). After the UV irradiation, the aluminum foil was peeled off, and the samples (seedle bran extract and arbutin) were applied in the following manner. Pigmentation appeared 2-3 days after UV irradiation and reached a peak after about 2 weeks, from which each sample was applied.
도포회수는 1일 1회 또는 2회로, 50일간 계속하였다. 시료는 특정한 용매(프로필렌 글리콜 : 에탄올 : 물 = 5 : 3 : 2의 혼합용매)를 사용하여 용해 및 희석하였으며, 면봉으로 도포하고, 다른 부위에 반드시 용매를 도포하는 대조부위를 마련하였다. 효과 판정과 함께 누적자극성 여부도 관찰하였다. The number of coatings was continued once or twice a day for 50 days. The sample was dissolved and diluted using a specific solvent (propylene solvent: ethanol: water = 5: 3: 2: mixed solvent), and applied with a cotton swab, and prepared a control site for necessarily applying the solvent to other sites. Along with the determination of effects, the cumulative stimulus was also observed.
색차계(CR2002 chromameter, 미놀타, 일본)를 사용하여 피부의 흑백정도를 측정하여 효과를 판정하였으며, 그 결과를 하기 표 3에 나타내었다. 색을 표시하는데는 L*A*B* 표색계를 사용하며, 본 발명에서는 L*값을 지표로 하였다. L*값은 표준 백판으로 교정하며, L*값은 1개 부위에 5회 이상 반복하여 측정하였고, 색소침착을 균등하게 하였다. 도포 시작시점과 완료시점에서의 피부색의 차이(△L*)를 구하고(하기 수학식 1 참조) 이 값으로 효과를 판정하였다. 그 결과를 하기 표 3에 나타내었다.The effect was determined by measuring the degree of black and white of the skin using a color difference meter (CR2002 chromameter, Minolta, Japan), the results are shown in Table 3 below. L * A * B * color system is used to display color, and L * value was used as an index in this invention. L * value was calibrated with a standard whiteboard, and L * value was measured 5 times or more at one site, and pigmentation was equalized. The difference (ΔL * ) of the skin color at the start and completion of the application was determined (see Equation 1 below), and the effect was determined using this value. The results are shown in Table 3 below.
△L* 값을 시료도포 부위와 대조군 부위에 대해서 구한 후 비교하면 미백물질의 효과를 알 수 있다.Comparing the ΔL * value with respect to the sample application site and the control site, the effect of the whitening material can be seen.
상기 표 3에 기재된 바와 같이, 참가죽그물바탕말 추출물은 농도-의존적으로 미백효과를 나타내었다. 또한, 참가죽그물바탕말 추출물은 알부틴보다 우수한 미백효과를 보였으며, 시험물질 도포시험 중 누적 자극을 보이는 것은 관찰되지 않아 안전성 또한 우수한 것으로 나타났다.As shown in Table 3 above, the participating bamboo grass extract showed a concentration-dependent whitening effect. In addition, Participants extract showed better whitening effect than Arbutin, and cumulative irritation was not observed during application test.
실시예 5 : 참가죽그물바탕말 추출물의 인체 피부에 대한 안전성 확인 실험Example 5 Safety Confirmation Test of Human Participate
5-1: 참가죽그물바탕말 추출물을 포함한 피부외용제의 제조5-1: Preparation of External Skin Agents Containing Participant Extract
상기와 같이 미백효과가 우수하다고 판명된 참가죽그물바탕말 추출물이 인체피부에도 안전한지 확인하기 위하여, 참가죽그물바탕말 추출물 및 알부틴을 함유한 피부외용제를 제조하고 이에 의한 피부 안전성 검증 실험을 수행하였다.In order to confirm that the participating bamboo bark extract was found to be excellent in the whitening effect as described above, it is also safe for human skin, a skin external preparation containing the participating bark extract and arbutin was prepared and skin safety verification experiment was conducted. It was.
참가죽그물바탕말 추출물과 알부틴을 함유한 피부외용제는 하기 표 4의 성분함량으로 제조하였다. 하기 표 4에서 대조군은 타이로시네이즈 저해제를 포함하지 않은 피부외용제이며, 시험군 1과 시험군 2는 각각 참가죽그물바탕말 추출물과 알부틴을 포함한 피부외용제이다.The skin external preparations containing the extracts of bark horseweed and arbutin were prepared according to the ingredients in Table 4 below. In the following Table 4, the control group is a skin external preparation that does not include a tyrosinase inhibitor, and test group 1 and test group 2 are external skin preparations including the extracts of moths and arbutin.
피부외용제 제조를 위하여, 정제수, 세린 및 부틸렌글리콜을 혼합하고 70 ℃에서 용해하였으며(수상파트), 상기 세 성분과 트리메탄올아민을 제외한 나머지 성분을 70 ℃에서 용해하였다(유상파트). 상기 오일파트를 수상파트에 첨가하고 호모믹서(도쿠슈 키카, 일본)로 교반하여 1차 유화하였고, 여기에 트리메탄올아민을 최종 첨가하였다. 혼합액에 생성된 기포를 제거한 후, 실온으로 냉각시켜 피부외용제를 제조하였다.For the preparation of external skin preparations, purified water, serine and butylene glycol were mixed and dissolved at 70 ° C. (aqueous part), and the other components except the three components and trimethanolamine were dissolved at 70 ° C. (oil phase part). The oil part was added to the water part and stirred with a homomixer (Tokushu Kika, Japan) to emulsify first, to which trimethanolamine was finally added. After removing the bubbles generated in the mixed solution, and cooled to room temperature to prepare a skin external preparation.
5-2: 피부누적 자극 시험5-2: Accumulated skin irritation test
상기 실시예 4-1에서 제조한 각 피부외용제를 사용하여 건강한 30명의 성인을 대상으로 윗팔뚝 부위에 격일로 총 9회의 24시간 누적첩포를 시행하는 것에 의하여 참가죽그물바탕말 추출물이 피부에 자극을 주는지의 여부를 측정하였다.Participating bamboo root extract was irritated to the skin by subjecting the upper forearm to a total of nine 24-hour cumulative patches every other day for 30 healthy adults using the skin preparations prepared in Example 4-1. It was measured whether or not to give.
첩포 방법은 핀 챔버(Finn chamber, Epitest Ltd, 핀란드)를 이용하였다. 챔버에 상기 각 피부외용제를 15 ㎕씩 적하한 후 첩포를 실시하였다. 매회 피부에 나타난 반응의 정도를 아래의 수학식 2를 이용하여 점수화 하였으며, 그 결과를 하기 표 5에 나타내었다.The patch method used the fin chamber (Finn chamber, Epitest Ltd, Finland). 15 µl of each of the external skin preparations was added dropwise to the chamber, followed by patching. The degree of response to the skin each time was scored using Equation 2 below, and the results are shown in Table 5 below.
이 때, 반응도에서 ± 는 1점, +는 2점, ++는 4점의 점수를 부여하며, 평균 반응도가 3 미만일 때 안전한 조성물로 판정하였다.At this time, ± 1 point, + 2 points, + + 4 points in the reaction degree, and when the average reactivity is less than 3 was determined as a safe composition.
상기 표 5에서 시험군 1과 2의 경우, ± , + 및 ++에 해당하는 사람의 수가 각각 3명, 0명 및 1명이었고, 그 외 나머지는 반응이 나타나지 않았다. 상기 기재된 식에 따라 계산하면 평균 반응도가 0.37이 되어 3이하가 되어 안전한 조성물로 판단되었다. In Test Tables 1 and 2 in Table 5, the number of people corresponding to ±, +, and ++ was 3, 0, and 1, respectively, and the rest did not appear. When calculated according to the formula described above, the average reactivity was 0.37, which was 3 or less, which was determined to be a safe composition.
상기 표 5에 기재된 바와 같이, 참가죽그물바탕말 추출물(시험군 1)을 포함한 피부외용제는 대조군이나 알부틴을 포함한 피부 외용제와 같이 뚜렷한 누적자극 양상을 나타내지 않았으며 인체 피부에 안전한 물질로 판정되었다.As shown in Table 5, the external skin preparations containing the extracts of the Participating bark horseweed extract (Test Group 1) did not show a distinct cumulative stimulation pattern as the skin external preparations including the control group or arbutin and were determined to be safe for human skin.
실시예 6: 참가죽그물바탕말 추출물의 항산화 효과Example 6 Antioxidant Effect of Participating Grain Extract
수퍼옥사이드 디스뮤타아제(Superoxide dismutase)(SOD)는 수퍼옥사이드 음이온(Superoxide anion)를 H2O2와 O2로 전환시키는 항산화효소로 알려져 있다. 이 실험은 잔틴 옥시다아제(Xanthine oxidase)에 의해 발생한 수퍼옥사이드 음이온이 시험에 사용된 시료에 의해 제거된 비율을 관찰함으로써, 시료의 항산화능을 평가하는 방법이다. 실험은 Dojindo(일본)에서 구입한 키트(SOD Assay Kit-WST)를 사용하여 실시하였으며, 제조사의 프로토콜에 따라 실험하였다. 간략하게 효과는 시료에 의한 수퍼옥사이드 음이온 제거율을 관찰함으로써, 항산화기능의 유무를 판단하였다. 실험 결과를 표 6에 나타냈다.Superoxide dismutase (SOD) is known as an antioxidant that converts superoxide anions into H 2 O 2 and O 2 . This experiment is a method of evaluating the antioxidant capacity of a sample by observing the rate at which the superoxide anion generated by Xanthine oxidase was removed by the sample used in the test. The experiment was carried out using a kit purchased from Dojindo (Japan) (SOD Assay Kit-WST), and was tested according to the manufacturer's protocol. In brief, the effect was determined by observing the removal rate of superoxide anion by the sample, the presence or absence of antioxidant function. The experimental results are shown in Table 6.
상기 표 6에 기재된 바와 같이, 본 발명의 참가죽그물바탕말 추출물은 농도-의존적으로 항산화효과를 가지고 있음을 알 수 있었다.As shown in Table 6, it was found that the participating bamboo bark extract of the present invention has an antioxidant effect in a concentration-dependent manner.
실시예 7 : 참가죽그물바탕말 추출물의 항염증 효능 평가Example 7 Evaluation of Anti-Inflammatory Effect of Participation
참가죽그물바탕말 추출물의 항염증 효과를 살펴보기 위하여 인간단핵구 세포인 THP-1 세포에서의 통상의 방법에 따라 COX 활성억제능 실험을 시행하였다. COX 활성 측정은 F. J. Van de Ouderaa and M Buytenhek가 발표한 Method in Enzymology 43:9(1994)에 따라 시행하였다. THP-1 세포주(한국세포주은행)를 배양한 다음 24-웰 플레이트에 세포들을 분주하였다. 웰 당 인큐베이션 부피는 500㎕로 맞추고, LPS(lipopolysaccharide, Sigma)(1 ㎍/ml)와 하기 표에 표기된 용매에 각각 녹인 시료 2 ㎕를 첨가한 다음 24 - 48시간 동안 같은 조건으로 배양하였다. 24 - 48시간 후 각 웰에 칼슘 이오노포어(calcium ionophore, Sigma)와〔1-14C〕아라키돈산 1 ㎕(in EtOH, 0.1 μCi/ml, Sigma)를 첨가하고 같은 조건으로 10분간 배양하였다. 배양 후 각 웰에 시트르산을 첨가하여 pH를 3.5로 맞추어 흔들어 준 다음 각 배양액을 500 ㎕ 취하여 마이크로원심분리기 튜브에 분주한 다음 에틸아세테이트 700 ㎕를 첨가하여 10분 동안 진탕 추출하였다. 에틸아세테이트층을 500 ㎕ 취하여 스피드 진공 건조기를 이용하여 20분 동안 농축하고 농축한 잔여부분을 20 ㎕ 에틸아세테이트로 녹인 다음 TLC 플레이트에 어센틱 스탠다드(authentic standard)와 함께 적용하였다. 방사능 밴드는 어센틱 이오코사노이드 스탠다드(authentic eicosanoid standards)로 확인하였고, 확인된 밴드의 방사능은 BAS 2000 바이오-이메이징 어넬라이저(bio-imaging analyzer)(Fuji, 일본)를 이용하여 측정하였다(표 7).In order to examine the anti-inflammatory effects of the extracts of the fungi, we conducted COX activity inhibitory experiments according to the conventional method in THP-1 cells, which are human monocytes. COX activity was measured according to Method in Enzymology 43: 9 (1994) published by FJ Van de Ouderaa and M Buytenhek . THP-1 cell line (Korea Cell Line Bank) was cultured and the cells were dispensed in 24-well plates. The incubation volume per well was adjusted to 500 μl, and 2 μl of sample dissolved in LPS (lipopolysaccharide, Sigma) (1 μg / ml) and the solvent shown in the following table was added, and then incubated under the same conditions for 24 to 48 hours. After 24 to 48 hours, 1 μl of calcium ionophore (Sigma) and [1-14C] arachidonic acid (in EtOH, 0.1 μCi / ml, Sigma) were added to each well and incubated for 10 minutes under the same conditions. After incubation, citric acid was added to each well, and the pH was adjusted to 3.5. Then, 500 μl of each culture solution was aliquoted into a microcentrifuge tube, and 700 μl of ethyl acetate was added thereto, followed by shaking extraction for 10 minutes. 500 µl of ethyl acetate layer was taken and concentrated for 20 minutes using a speed vacuum dryer. The concentrated residue was dissolved in 20 µl of ethyl acetate and applied to an TLC plate with an authentic standard. Radioactivity bands were identified by authentic eicosanoid standards, and the radioactivity of the identified bands was measured using a BAS 2000 bio-imaging analyzer (Fuji, Japan) (Table 7). .
상기 표 7에 기재된 바와 같이, 본 발명의 참가죽그물바탕말 추출물은 처리농도가 증가할수록 COX의 활성을 효과적으로 억제하고 있음을 알 수 있었으며, 이를 통해 염증억제 효능이 있음을 알 수 있었다.As shown in Table 7, it can be seen that the participating bamboo bark extract of the present invention effectively inhibits the activity of COX as the treatment concentration is increased, and it can be seen that there is an effect of inhibiting inflammation.
실시예 8 : 참가죽그물바탕말 추출물의 면역억제능 평가Example 8: Evaluation of immunosuppressive ability of the extract
본 발명의 참가죽그물바탕말 추출물이 염증과 관련된 면역관련 반응을 억제하는지의 여부를 인터루킨-2 루시퍼라아제 리포터(interleukin-2 luciferase reporter) 활성실험을 통해 조사하였다. 인터루킨-2 프로모터는 염증과 관련된 면역관련 사이토카인의 생산에 중요한 역할을 한다고 보고되어 있다. 인터루킨-2 루시퍼라아제 활성을 측정하기 위해서 다음과 같은 방법을 사용하였다. 인간 T림프구세포주인 Jurkat 세포(한국세포주은행)를 6 웰에 각각 1x106 개의 세포를 분주한 후, 수퍼펙트 트란스펙션 리에전트(superfect transfection reagent)(In vitrogen)를 이용하여 인터루킨-2 루시퍼라아제 리포터 플라스미드 DNA(IL-2 luciferase reporter plasmid DNA)를 형질감염(transfection)시켰다. 형질감염 후 24시간이 경과한 후, PHA(Phytohemaglutinin, Sigma) (100 ng/ml)를 처리하여 Jurkat 세포를 활성화시킴과 동시에 각각의 시료를 농도별로 처리하였다. 24시간 후 세포를 수집하여 루미노미터(luminometer)(Berthold Technologies GmbH&Co.KG, 독일)를 이용하여 루시퍼라아제 활성을 측정하였다. 결과를 정리하면 다음과 같다.Whether or not the extract of the bark of the present invention inhibits an immune related response related to inflammation was investigated through an interleukin-2 luciferase reporter activity test. The interleukin-2 promoter is reported to play an important role in the production of immune-related cytokines associated with inflammation. The following method was used to measure interleukin-2 luciferase activity. After dispensing 1 × 10 6 cells into 6 wells of Jurkat cells (Korea Cell Line Bank), which is a human T lymphocyte cell line, interleukin-2 lucifera using a superperfect transfection reagent (In vitrogen) was used. Aze reporter plasmid DNA (IL-2 luciferase reporter plasmid DNA) was transfected. After 24 hours after transfection, PHA (Phytohemaglutinin, Sigma) (100 ng / ml) was treated to activate Jurkat cells and each sample was treated by concentration. After 24 hours, cells were collected and luciferase activity was measured using a luminometer (Berthold Technologies GmbH & Co.KG, Germany). The results are as follows.
상기 표 8에 기재된 바와 같이, 참가죽그물바탕말 추출물은 처리농도가 증가할수록 인터루킨-2의 발현을 억제함으로써 면역조절기능을 가지고 있음을 알 수 있었다.As shown in Table 8, it was found that the participating bamboo grass extract has an immunomodulatory function by inhibiting the expression of interleukin-2 as the treatment concentration increases.
실시예 9: 참가죽그물바탕말 추출물의 주름개선 효과 측정Example 9 Measurement of Wrinkle Improvement Effect of Participants
주름개선효과는 통상 콜라겐 생합성능과 콜라게네이즈 분해 억제능 및 사람에 대한 임상시험으로서 효과를 측정할 수 있다. The anti-wrinkle effect can usually be measured as collagen biosynthesis and collagenase degradation inhibitory effect and clinical trial in humans.
사람의 정상 섬유 아세포 (Human normal fibroblast, (주)태평양)를 DMEM 배지가 들어 있는 6-웰 마이크로 플레이트에 접종시키고 (2 X 105 세포/웰) 5% 농도의 CO2 배양기에 37℃로 24시간 배양하였다. 24시간 후, 각 웰에서 배지를 제거하고 농도별로 시료를 처리한 다음 24시간 동안 다시 배양하였다. 24시간 후, 세포배지를 수집하여 샘플을 제조하였다. Human normal fibroblasts (Pacific) were inoculated into 6-well microplates containing DMEM medium (2 × 10 5 cells / well) in a 2% CO 2 incubator at 37 ° C. Time incubation. After 24 hours, the medium was removed from each well, samples were treated by concentration and then incubated again for 24 hours. After 24 hours, cell media were collected to prepare samples.
콜라겐 합성량은 콜라겐 측정 키트 (Procollagen Type I C-peptide EIA kit (MK101), 다카라, 교토, 일본)를 이용하여 제조사의 프로토콜에 따라 세포배지 내에서의 프로콜라겐(procollagen) 타입 I C-펩타이드(Type I C-peptide: PICP)의 양을 측정, 분석하였다.Collagen synthesis amount was measured by using the collagen measurement kit (Procollagen Type I C-peptide EIA kit (MK101), Takara, Kyoto, Japan) according to the manufacturer's protocol. The amount of Type I C-peptide (PICP) was measured and analyzed.
콜라겐을 분해하는 효소인 콜라게네이즈의 활성정도를 측정하는 방법으로 콜라게네이즈에 대한 항체를 이용하였다. 콜라게네이즈 활성은 타입 I 콜라게네이즈 어세이 키트(Amersham Biosciences, RPN2629)를 이용하였으며, ELISA 판독기(Bio-Tek ELx808™ Series Ultra Microplate Reader, 영국)로 흡광도를 측정하였다. 측정된 표준치는 평균±표준편차의 형태로 표시하였고 SPSS/PC+ 프로그램을 이용하여 t-test로 유의성을 검정하였다. 그 결과를 하기 표 9에 나타내었다.An antibody against collagenase was used as a method for measuring the activity of collagenase, an enzyme that degrades collagen. Collagenase activity was measured using a type I collagenase assay kit (Amersham Biosciences, RPN2629) and absorbance was measured with an ELISA reader (Bio-Tek ELx808 ™ Series Ultra Microplate Reader, UK). The measured standard values were expressed in the form of mean ± standard deviation and tested for significance by t-test using the SPSS / PC + program. The results are shown in Table 9 below.
추출물 (1ppm)Participation
Extract (1 ppm)
추출물 (5ppm)Participation
Extract (5 ppm)
추출물 (10ppm)Participation
Extract (10 ppm)
표 9에 나타난 바와 같이, 참가죽그물바탕말 추출물은 농도-의존적으로 콜라겐 합성을 증가시켰으며, 또한 농도-의존적으로 콜라게네이즈 활성을 억제하였다. 따라서, 참가죽그물바탕말 추출물은 주름개선 효능을 가지고 있음을 알 수 있었다.As shown in Table 9, the Participants extract increased collagen synthesis concentration-dependently, and also inhibited collagenase activity concentration-dependently. Therefore, it was found that the participating bamboo grass extract has an effect of improving wrinkles.
실시예 10: 참가죽그물바탕말 추출물의 항비만 효과(경구투여)Example 10: Anti-obesity Effect of Participating Grain Horsetail Extract (Oral)
10-1: 리포좀 제형 제조10-1: Liposomal Formulation Preparation
1). 유상 성분 중 레시틴, 에탄올, 세라마이드, 콜레스테롤에스터, 스쿠알란, 카프릴릭카프릭트리글리세라이드, 피토스테롤를 계량하여 온도(60∼65℃)를 올린 후 아지 믹서(agi mixer)를 150rpm 속도로 교반하여 용해시킨다. One). Lecithin, ethanol, ceramide, cholesterol ester, squalane, caprylic capric triglyceride and phytosterol in the oil phase components were measured and the temperature was raised (60-65 ° C.), followed by dissolving the azi mixer at 150 rpm.
2). 수상 성분에서 보습성분인 글레세린, 하이알루로닉 애씨드,소르비톨를 계량하여 온도(60∼65℃)를 올린 후 아지 믹서(agi mixer)를 150rpm 속도로 교반하여 용해시킨다. 2). The moisturizing ingredients glycerin, hyaluronic acid, and sorbitol are measured in the aqueous phase to raise the temperature (60 to 65 ° C.), and then the azi mixer is stirred at 150 rpm to dissolve.
3). 유화직전에 유효성분 참가죽그물마탕말(0.1%, 1%)를 첨가한다.3). Just before emulsification, add the active ingredient bamboo mat powder (0.1%, 1%).
4). 수상성분과 유상성분의 온도는 60∼65℃ 유지하고 수상성분의 아지 믹서의 교반은 100rpm , 호모 믹서는 3,000rpm으로 유지하면서 유상성분을 천천히 투입한다(유화시간: 5min) 4). The temperature of the water phase component and oil phase component is maintained at 60 to 65 ° C., while the azi mixer of the water phase component is stirred at 100 rpm and the homo mixer at 3,000 rpm, and the oil phase component is slowly added (emulsion time: 5 min).
5). 유화를 한후 내용물을 냉각기로 통과시켜 30℃까지 냉각시킨다, 그리고 마이크로플루다이져에 3회통과를 한다5). After emulsification, the contents are passed through a cooler and cooled to 30 ℃, and then passed through a microfluidizer three times.
6). 교반하면서 점증제를 서서히 넣어 엉기지 않도록 골고루 분산한후 40℃까지 냉각시킨후 방부제 및 첨가원료(토코페롤 등)를 투입하면서 아지 믹서(agi mixer)를 150rpm 속도로 교반하여 분산용해한다. 6). After stirring, the thickener is gradually added to prevent tangling, and the mixture is cooled to 40 ° C., and then preservatives and additives (tocopherol, etc.) are added to disperse and dissolve the azi mixer at a speed of 150 rpm.
7). 진공 펌프를 작동하여 혼합 탱크의 내부 상태를 진공으로 걸었다가 바람을 빼는 식의 반복된 연속적인 동작으로 10분 동안 탈기를 한다. 7). A vacuum pump is operated to degas the mixing tank for 10 minutes in a continuous, bleeding manner, by vacuuming the inside of the mixing tank.
8). 28∼30℃까지 냉각후 냉각된 반제품은 200메시의 여과망을 통과시켜 이물질을 제거한 후 저장 용기에 담 아 실온(25±2℃)에 보관한다. 8). After cooling to 28 ~ 30 ℃, the semi-finished product is passed through a 200 mesh filter screen to remove foreign substances, and then stored in a storage container at room temperature (25 ± 2 ℃).
10-2: 경구투여를 통한 비만억제 효과10-2: Anti-obesity effect by oral administration
비만억제시험은 생후 7주된 ICR 계 수컷 마우스(챨스리버(주), 일본)를 1주일 동안 예비사육한 후, 1군 7마리로 실험에 사용하였다. 동물은 온도 23±1℃, 습도 55±5%, 조명시간 12시간/일(day)로 설정된 항온항실에서 사육하였고, 라보MR (일본농산공업 제조) 사료를 일정 시간 간격으로 제공하여 섭취토록 하였으며, 물은 자유롭게 섭취할 수 있도록 하였다. 참가죽그물바탕말 추출물은 0.1%, 1%가 되도록 10-1의 제조방법을 이용하여 리포좀 제형(레시틴 5%에 녹인 것)으로 제조하였다. 각 시료 용액은 마우스 10 g당 0.1 ml 투여되도록 농도 조정하였으며, 투여량을 1.5 g/kg 및 1 g/kg으로 하였다. 또한, 대조군은 5% 레시틴 에멀젼으로 하여 동일한 양으로 투여하였다. 마우스는 투여하기 전날부터 절식(絶食) 상태로 하여 다음 날 강제로 단회(單回) 투여하였다. 시험기간은 2주일로 하고, 체중 및 일반증상을 측정, 관찰하였다. The obesity suppression test was carried out with 7 weeks old ICR male mice (Chicks River Co., Ltd., Japan) for 1 week, and then used in experiments in 7 groups. Animals were raised in a constant temperature room set at a temperature of 23 ± 1 ℃, a humidity of 55 ± 5% and an illumination time of 12 hours / day. In addition, water was freely consumed. Participating ginseng extract was prepared as a liposome formulation (dissolved in 5% lecithin) using the preparation method of 10-1 to be 0.1%, 1%. Each sample solution was adjusted to a concentration of 0.1 ml per 10 g of mouse, and doses were 1.5 g / kg and 1 g / kg. In addition, the control group was administered in the same amount as a 5% lecithin emulsion. Mice were fasted from the day before administration and were forcibly administered once the next day. The test period was two weeks, and body weight and general symptoms were measured and observed.
제형Liposomes
Formulation
상기 표 10에서 확인할 수 있듯이, 참가죽그물바탕말 추출물은 비만억제 효과를 나타내었다. 투여 농도가 높아질수록 그 효능이 우수함을 관찰할 수 있었다.As can be seen in Table 10, the participating bamboo net extract showed an anti-obesity effect. It was observed that the higher the dosage concentration, the better the efficacy.
실시예 11: 참가죽그물바탕말 추출물의 탈모방지 및 육모효과Example 11 Hair Loss Prevention and Hair Growth Effect of P.
본 발명에 따른 참가죽그물바탕말의 탈모방지와 육모 효과에 대하여 알아보기 위하여, 하기와 같은 실험을 수행하였다.In order to find out about the hair loss prevention and hair growth effect of the participating bamboo net horse according to the invention, the following experiment was performed.
1. 발모제 조성물의 제조1. Preparation of Hair Regrowth Composition
참가죽그물바탕말을 함유한 발모제 조성물은 하기 표의 성분 함량으로 하여 하이드로젤 베이스를 제조하였다. The hair restorer composition containing the bamboo flakes was prepared as the component content of the following table.
상기 제조한 발모촉진용 외용액제를 이용하여 약화 또는 방사능노출에 따른 탈모 환자 10명의 탈모부위에 1일 2회 각각 3㏄씩 6개월간 적용하였다. 대조구로서 한미약품에서 판매 중인 목시딜을 사용하였다. 그 결과를 하기 표 12에 나타내었으며, 탈모 환자 8명에게서 새로운 모근이 발생하는 등의 우수한 효과가 있는 것으로 나타났다. Using the external preparation for promoting hair growth, the hair loss site of 10 patients with alopecia due to weakening or radioactive exposure was applied twice a day for 3 months each for 3 months. As a control, moxidil sold in Hanmi Pharm was used. The results are shown in Table 12 below, and showed excellent effects such as the occurrence of new hair roots in eight hair loss patients.
[판정기준][Criteria]
4: 높은 효과 있음=신생모가 보임,4: high effect = newborn hair visible,
3: 중간 정도의 효과 있음=신생모가 보임(솜털),3: moderate effect = visible newborn hair (downy),
2: 약간 효과 있음=탈모의 수가 감소함,2: slightly effective = the number of hair loss decreases,
1: 효과 없음=전혀 변화가 보이지 않음.1: no effect = no change at all.
상기 표 12에서 확인할 수 있듯이, 본 발명의 참가죽그물바탕말 추출물을 도포하였을 경우, 신생모 생성을 유도하는 발모 효능을 나타내었다.As can be seen in Table 12, when the participating bamboo bark horse extract of the present invention was applied, it showed a hair growth effect inducing the generation of new hair.
본 발명의 참가죽그물바탕말 추출물은 피부 염증 억제, 주름 개선, 노화 방지, 발모 촉진, 항산화 및 항비만 효과를 가지고 있어서, 화장료, 약품 및 식품에 함유하여 유용하게 사용할 수 있다.Participating ginseng extract of the present invention has skin inflammation suppression, wrinkle improvement, anti-aging, hair growth promotion, antioxidant and anti-obesity effect, and can be usefully contained in cosmetics, drugs and foods.
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090007594A KR101070886B1 (en) | 2009-01-30 | 2009-01-30 | A composition comprising pachydictyon coriaceum extract |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020090007594A KR101070886B1 (en) | 2009-01-30 | 2009-01-30 | A composition comprising pachydictyon coriaceum extract |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20100088397A KR20100088397A (en) | 2010-08-09 |
KR101070886B1 true KR101070886B1 (en) | 2011-10-06 |
Family
ID=42754619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090007594A KR101070886B1 (en) | 2009-01-30 | 2009-01-30 | A composition comprising pachydictyon coriaceum extract |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101070886B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101434446B1 (en) * | 2011-08-12 | 2014-08-29 | 재단법인 제주테크노파크 | Composition for External Application to the Skin Using an Extract of Dictyota dichotoma |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100873180B1 (en) * | 2007-11-05 | 2008-12-10 | 신라대학교 산학협력단 | An antibacterial composition comprising an extract of brown algae |
-
2009
- 2009-01-30 KR KR1020090007594A patent/KR101070886B1/en active IP Right Grant
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100873180B1 (en) * | 2007-11-05 | 2008-12-10 | 신라대학교 산학협력단 | An antibacterial composition comprising an extract of brown algae |
Also Published As
Publication number | Publication date |
---|---|
KR20100088397A (en) | 2010-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100823533B1 (en) | COMPOSITIONS FOR IMPROVING SKIN CONDITIONS COMPRISING alpha;-BISABOLOL AS AN ACTIVE INGREDIENT | |
KR100862968B1 (en) | Agents for Improving Wrinkles on Skin Comprising Matrine or Its Oxidized Derivatives | |
KR101819727B1 (en) | Composition containing ginseng berry extract using processing of herbal medicine | |
KR102126470B1 (en) | Cosmetic Composition for comprising longanae arillus extracts | |
KR100848800B1 (en) | Skincare composition containing brazilian pepper oil | |
US20200078290A1 (en) | Cosmetic Composition Comprising Extract Of Medicinal Herbs As Active Ingredient | |
KR100639408B1 (en) | Cosmetic composition comprising the extract of Bambusae Folium showing inhibitory effect and whitening effect on UV-induced skin damage | |
KR101070886B1 (en) | A composition comprising pachydictyon coriaceum extract | |
KR101223684B1 (en) | Compositions for Improving Skin Conditions Comprising Afzelin as an Active Ingredient | |
KR20190036060A (en) | Skin-lightening Composition Using an Extract of Polygonum amphibium | |
KR101924446B1 (en) | Composition containing ginseng berry extract using processing of herbal medicine | |
KR100862969B1 (en) | Agents for skin whitening comprising barbituric acid as an active ingredient | |
EP3318246B1 (en) | Whitening cosmetic composition comprising caragana sinica | |
CN101543525B (en) | Beauty composition containing vaccinium vitis-idaea extract and application thereof | |
KR100863616B1 (en) | Skincare composition containing copaiba balsam oil | |
CN110974737A (en) | Composition for improving skin comprising pueraria lobata extract or compound derived therefrom | |
KR100823537B1 (en) | Compositions for Anti-obesity Comprising α-Bisabolol as an Active Ingredient | |
KR101244653B1 (en) | Compositions for Improving Skin Conditions Comprising Ginsenoside Rb3 as an Active Ingredient | |
KR102016641B1 (en) | Composition containing extract using process of herbal medicine | |
KR100875755B1 (en) | Skin condition improvement composition comprising leaf greens extract as the main active ingredient | |
KR100862967B1 (en) | Compositions for Anti-Obesity Comprising Matrine or Its Oxidized Derivatives | |
KR100930592B1 (en) | Skin whitening and antioxidant composition containing extracts against | |
KR20080102752A (en) | Compositions for improving skin conditions comprising isorhamnetin as an active ingredient | |
KR100845888B1 (en) | Compositions for improving skin conditions comprising breu branco essential oil as an active ingredient | |
KR100823535B1 (en) | Compositions for Stimulating Hair Growth Comprising α-Bisabolol as an Active Ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20140709 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150903 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20160629 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20170620 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20180620 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20190809 Year of fee payment: 9 |